Tokyo, June 26, 2019 - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has been named to the FTSE4Good Index Series for the eighth consecutive year. Astellas was recognized this year for its strong performance for the following categories: Climate Change, Labor Standards, and Corporate Governance.
Created by the FTSE Russell1, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. The FTSE4Good Indices are used by a wide variety of market participants to create and assess sustainable investment funds and other products.
In addition to the FTSE4Good Index Series, Astellas has been named to all ESG investment indices selected by the Government Pension Investment Fund of Japan which are FTSE Blossom Japan Index, MSCI Japan ESG Select Leaders Index, MSCI Japan Empowering Women Index (WIN), and S&P/JPX Carbon Efficient Index.
By fulfilling its corporate social responsibility as a pharmaceutical company, Astellas strives to improve a sustainable increase in enterprise value.